To summarize recent advances in the study of drug-tolerant persister (DTP) cells in lymphoid malignancies and explore their mechanisms of persistence and resistance, with a focus on their implications for treatment.
Approach:
Overview of DTP Cells: Discusses the emergence of DTP cells as a model for understanding resistance mechanisms in lymphoid malignancies.
Mechanisms of Resistance: Explores gene-regulatory changes, cell surface remodeling, and immune evasion strategies contributing to DTP cell persistence.
Experimental Models: Highlights various experimental approaches for investigating DTP cells, including co-culture systems.
Therapeutic Avenues: Identifies potential treatment strategies targeting glycosylation-related pathways and immunotherapeutic glycopeptide targets, as well as rational combination regimens.
Key Findings:
DTP cells arise in response to chemotherapy and adopt a quiescent state to endure drug exposure.
Resistance mechanisms in DTP cells are primarily driven by non-genetic adaptations.
A subset of DTP cells may evolve into drug-tolerant expanded persister (DTEP) cells through genomic alterations.
Interpretation:
The review aims to broaden current theories on therapy resistance in lymphoid malignancies by integrating insights from DTP biology.
Limitations:
The direct applicability of the cancer stem cell hypothesis in lymphoid malignancies remains limited.
Further research is needed to fully understand the complexity of therapy resistance mechanisms in the context of DTP cells.
Conclusion:
Understanding DTP cells is essential for developing therapeutic strategies and addressing minimal residual disease in lymphoid malignancies.
